Michiaki Koga

Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study

James F. Howard, Kimiaki Utsugisawa, Michael Benatar et al. · The Lancet Neurology · 2017 · 745 citations

Multicentre Study, Pharmacology, Medicine +3

Carbohydrate mimicry between human ganglioside GM1 and <i>Campylobacter jejuni</i> lipooligosaccharide causes Guillain–Barré syndrome

Nobuhiro Yuki, Keiichiro Susuki, Michiaki Koga et al. · Proceedings of the National Academy of Sciences · 2004 · 493 citations · Full text

Anti-gm1 Antibody, Microbial Pathogens, Immunodeficiencies +24

Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis

Minoru Nakamura, Hisayoshi Kondo, Tsuyoshi Mori et al. · Hepatology · 2006 · 353 citations · Full text

Axonal Guillain-Barr� syndrome: Relation to anti-ganglioside antibodies andCampylobacter jejuni infection in Japan

Kazue Ogawara, Satoshi Kuwabara, Masahiro Mori et al. · Annals of Neurology · 2000 · 325 citations

Animal model of axonal Guillain-Barré syndrome induced by sensitization with GM1 ganglioside

Nobuhiro Yuki, Mitsunori Yamada, Michiaki Koga et al. · Annals of Neurology · 2001 · 321 citations

Immunology, Peripheral Nerve, Peripheral Nerves +19